TAIPEI (Taiwan News) — Taiwan Bio-Medical Manufacturing Company said Friday its vaccine facility in Zhubei, Hsinchu County will go online next year.

TBMC CEO Chang Yu-hsiang (張幼翔) announced that plant construction will finish by year-end, with verification in Q1 2026 and full-scale production in Q2, per CNA. The plant will produce 13 million doses annually, with the ability to quadruple output in emergencies, he said at Bio Asia–Taiwan in Taipei.

The facility will support drug platforms including nucleic acid-based vaccines and cell therapies, using modular designs that meet international good manufacturing practice standards. It will also feature automated production lines for CAR-T and mesenchymal stem cell therapies.

TBMC noted strong international demand, with revenue in the first half of the year already 1.8 times last year’s full-year earnings, per MoneyDJ. The company’s contract research project volume also surged 70%, underscoring momentum as it transitions from R&D to mass production.

Chang said TBMC’s goal is to ensure Taiwan retains independent vaccine production capacity in future outbreaks. The company completed Series A fundraising last year, with about one-third of shares now publicly held, one-third owned by US partner Resilience, and the rest by private firms.

An IPO could be on the table but not yet. Chang said the company is focused on securing long-term orders and expects to go public within seven years if growth stays on track.